Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages
Authors:
- 17 April 2024
- Vol. 57 (5) , 1124-1140.e9
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01-CA262121)
- National Institutes of Health (R01-CA233512)
- National Institutes of Health (P01-CA250984)
- National Institutes of Health (R01-CA27303)
This publication has 64 references indexed in Scilit:
- Tumor-derived Jagged1 promotes cancer progression through immune evasionCell Reports, 2022
- High Dimensional Single-Cell Analysis Reveals iNKT Cell Developmental Trajectories and Effector Fate DecisionCell Reports, 2020
- Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer modelCancer Immunology, Immunotherapy, 2020
- Comprehensive Integration of Single-Cell DataCell, 2019
- DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest NeighborsCell Systems, 2019
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Jagged2‐signaling promotes IL‐6‐dependent transplant rejectionEuropean Journal of Immunology, 2013
- The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on AngiogenesisCell, 2009
- Notch signaling is activated by TLR stimulation and regulates macrophage functionsEuropean Journal of Immunology, 2007
- Notch signaling in differentiation and function of dendritic cellsImmunologic Research, 2007